C4 And Google's Calico Enter Mysterious Alliance On 'Diseases Of Aging'
Executive Summary
While details are scant, the five-year collaboration will pair C4's targeted protein degradation approach with Calico's focus on diseases of aging. Privately held C4 otherwise is aiming to bring its first Degronomid candidate into the clinic in 2018.